The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate

Drug Discovery Today: Technologies

Volumn 9, Issue 2, 2012, Pages

  Van Den Mooter, Guy ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DODECYL SULFATE SODIUM; ETRAVIRINE; EVEROLIMUS; GRISEOFULVIN; INDOPROFEN; ITRACONAZOLE; LOPINAVIR PLUS RITONAVIR; NABILONE; NILVADIPINE; NIMODIPINE; TACROLIMUS; TROGLITAZONE; VERAPAMIL;

AREA UNDER THE CURVE; ARTICLE; CHEMICAL COMPOSITION; DISPERSION; DRUG BIOAVAILABILITY; DRUG CONFORMATION; DRUG FORMULATION; DRUG MANUFACTURE; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; PHASE SEPARATION; SOLID DISPERSION; SOLID STATE; THERMOSTABILITY;

EID: 84868545732     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2011.10.002     Document Type: Review

References (41)

1. Lipinski, C.A. et al. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev. 46, 3-26
2. Amidon, G.L. et al. (1995) Theoretical basis for a biopharmaceutical drug classification; The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420
3. Singh, A. et al. (2011) Oral formulation strategies to improve solubility of poorly water-soluble drugs. Expert. Opin. Drug Deliv. 2, 1079-1091
4. Hilden, L.R. and Morris, K.R. (2004) Physics of amorphous solids. J. Pharm. Sci. 93, 3-12
5. Hancock, B. and Parks, M. (2000) What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res. 14, 397-404
6. Murdande, SB et al. Solubility advantage of amorphous pharmaceuticals, part 3: is maximum solubility advantage experimentally attainable and sustainable? J. Pharm. Sci., DOI:10.1002/jps.22643 (in press)
7. Chawla, G. and Bansal, A.K. (2007) A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug. Eur. J. Pharm. Sci. 32, 45-57
8. Murdande, S.B. et al. (2010) Solubility advantage of amorphous pharmaceuticals, part 1: Thermodynamic analysis. J. Pharm. Sci. 99, 1254-1264
9. Alonzo, D.E. et al. (2010) Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm. Res. 27, 608-618
10. Chiou, W.L. and Riegelman, S. (1971) Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. 60, 1281-1302
11. Six, K. et al. (2002) Thermal properties of hot-stage extrudates of itraconazole and eudragit E 100: phase separation and polymorphism. J. Therm. Anal. Calor. 68, 591-601
12. Vasanthavada, M. et al. (2005) Phase behaviour of amorphous molecular dispersions II: role of hydrogen bonding in solid solubility and phase separation kinetics. Pharm. Res. 22, 440-448
13. Baird, J.A. and Taylor, L.S. Evaluation of amorphous solid dispersion properties using thermal analytical techniques. Adv. Drug Del. Rev., DOI:10.1016/j.addr.2011.07.009 (in press)
14. Qian, F. et al. (2010) Is a distinctive single Tg a reliable indicator for the homogeneity of amorphous solid dispersion? Int. J. Pharm. 395, 232-235
15. Kalogeras, I.M. (2011) A novel approach for analyzing glass transition temperature vs composition patterns: application to pharmaceutical compound + polymer systems. Eur. J. Pharm. Sci. 42, 470-483
16. Newman, A. et al. (2008) Characterization of amorphous API:polymer mixtures using X-ray powder diffraction. J. Pharm. Sci. 97, 4840-4856
17. Ivanisevic, I. et al. (2009) Novel methods for the assessment of miscibility of amorphous drug-polymer dispersions. J. Pharm. Sci. 98, 3373-3386
18. Bates, S. et al. (2006) Analysis of amorphous and nanocrystalline solids from their X-ray diffraction patterns. Pharm. Res. 23, 2333-2349
19. Schantz, S. et al. (2009) A solid state NMR study of phase structure, molecular interactions and mobility in blends of citric acid and paracetamol. J. Pharm. Sci. 98, 1862-1870
20. Pham, T.N. et al. (2010) Analysis of amorphous solid dispersions using 2D solid state NMR and 1H T1 relaxation measurements. Mol. Pharm. 7, 1667-1691
21. Six, K. et al. (2003) Identification of phase separation in solid dispersions of itraconazole and eudragit E100 using micro-thermal analysis. Pharm. Res. 20, 135-138
22. Zhang, J. et al. (2009) Nanoscale thermal analysis of pharmaceutical solid dispersions. Int. J. Pharm. 380, 170-173
23. Qi, S. et al. (2011) Compositional analysis of low quantities of phase separation in hot melt extruded solid dispersions: a combined atomic force microscopy, photothermal Fourier-transform infrared microscopy and localized thermal analysis approach. Pharm. Res. 28, 2311-2326
24. Marsac, P.J. et al. (2006) Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm. Res. 23, 2417-2426
25. Janssens, S. et al. (2010) Influence of the preparation methods on solid state supersaturation of amorphous solid dispersions: a case study with itraconazole and eudragit E100. Pharm. Res. 27, 775-785
26. Paudel, A. et al. (2010) Theoretical and experimental investigation on the solid solubility and miscibility of naproxen in poly(vinylpyrrolidone). Mol. Pharm. 7, 1133-1148
27. Al-Obaidi, H. et al. (2011) Characterization and stability of ternary solid dispersions with PVP and PHPMA. Int. J. Pharm. 419, 20-27
28. Al-Obaidi, H. et al. (2009) Anomalous properties of spray dried solid dispersions. J. Pharm. Sci. 98, 4724-4737
29. Paudel, A and Van den Mooter, G. Influence of solvent composition on the miscibility and physical stability of naproxen/PVP K 25 solid dispersions prepared by cosolvent spray drying. Pharm. Res., DOI:10.1007/s11095-011-0539-x (in press)
30. Guns, S. et al. (2011) Comparison between hot-melt extrusion and spray drying for manufacturing of solid dispersions of the graft copolymer of ethylene glycol and vinylalcohol. Pharm. Res. 28, 673-682
31. Breitenbach, J. (2002) Melt extrusion: from process to drug delivery technology. Eur. J. Pharm. Biopharm. 54, 107-117
32. Dinunzio, J. et al. (2010) Fusion processing of itraconazole solid dispersions by Kinetisol dispersing: a comparative study to hot melt extrusion. J. Pharm. Sci. 99, 1239-1253
33. Janssens, S. and Van den Mooter, G. (2009) Physical chemistry of solid dispersions. J. Pharm. Pharmacol. 61, 1571-1586
34. Yoshioka, M. et al. (1994) Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J. Pharm. Sci. 83, 1700-1705
35. Grzybowska, K. et al. (2010) Molecular dynamics and physical stability of amorphous anti-inflammatory drug: Celecoxib. J. Phys. Chem. B 114, 12792-12801
36. Bhattacharya, S. and Suryanarayanan, R. (2011) Molecular motions in sucrose-PVP and sucrose-sorbitol dispersions: I. Implications of global and local mobility and stability. Pharm. Res. 28, 2191-2203
37. Zheng, X. et al. (2007) Part I: Characterization of solid dispersions of nimodipine prepared by hot-melt extrusion. Drug Dev. Ind. Pharm. 33, 791-802
38. Vertzoni, M. et al. (2004) Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects. J. Pharm. Pharmacol. 56, 453-462
39. Six, K. et al. (2005) Clinical study of itraconazole prepared by hot-stage extrusion. Eur. J. Pharm. Sci. 24, 179-186
40. Han, H-K. et al. (2011) Enhanced dissolution and bioavailability of biochanin A via the preparation of solid dispersion: in vitro and in vivo evaluation. Int. J. Pharm. 415, 89-94
41. Kararli, T. (1995) Comparison of the gastrointestinal anatomy, physiology and biochemistry of humans and commonly used laboratory animals. Biopharm. Drug Disp. 16, 351-380